Vicki Thallas-Bonke Selected Research

Inflammation (Inflammations)

1/2021	Processed foods drive intestinal barrier permeability and microvascular diseases.
1/2020	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility.
2/2016	Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
5/2015	AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vicki Thallas-Bonke Research Topics

Disease

19	Diabetic Nephropathies (Diabetic Nephropathy) 04/2021 - 01/2004
10	Albuminuria 04/2021 - 11/2004
5	Fibrosis (Cirrhosis) 04/2021 - 01/2013
4	Inflammation (Inflammations) 01/2021 - 05/2015
2	Chronic Disease (Chronic Diseases) 10/2011 - 07/2011
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2011 - 08/2005
1	Hyperglycemia 10/2017
1	Chronic Renal Insufficiency 01/2016
1	Diabetes Complications 05/2015
1	Diabetes Mellitus 05/2015
1	Body Weight (Weight, Body) 01/2014
1	Obesity 07/2011
1	Weight Gain 07/2011
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2010
1	Atherosclerosis 04/2007

Drug/Important Bio-Agent (IBA)

10	Advanced Glycation End ProductsIBA 01/2019 - 01/2004
4	Proteins (Proteins, Gene)FDA Link 10/2017 - 09/2006
4	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2017 - 02/2008
4	alagebriumIBA 10/2011 - 11/2004
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 02/2008
3	Protein Isoforms (Isoforms)IBA 01/2021 - 11/2004
3	Streptozocin (Streptozotocin)FDA Link 10/2017 - 06/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2016 - 11/2004
3	Receptor for Advanced Glycation End ProductsIBA 01/2014 - 08/2005
3	Superoxides (Superoxide)IBA 10/2011 - 04/2009
2	Complement C5a (Complement 5a)IBA 01/2021 - 01/2020
2	CollagenIBA 10/2017 - 01/2013
2	Fibronectins (Fibronectin)IBA 10/2017 - 11/2004
2	Apolipoproteins E (ApoE)IBA 06/2014 - 04/2007
2	Extracellular Matrix ProteinsIBA 06/2014 - 11/2004
2	AngiotensinsIBA 01/2010 - 08/2005
2	Protein Kinase C-alphaIBA 02/2008 - 11/2004
1	MitoGamideIBA 04/2021
1	Pyruvaldehyde (Methylglyoxal)IBA 04/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	NADP (NADPH)IBA 01/2021
1	alisporivirIBA 01/2020
1	Cyclophilins (Cyclophilin)IBA 01/2020
1	Mitochondrial Permeability Transition PoreIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	Complement System Proteins (Complement)IBA 01/2020
1	ChemokinesIBA 10/2017
1	TRPC6 Cation ChannelIBA 10/2017
1	nephrinIBA 02/2016
1	Apoptosis Inducing FactorIBA 01/2016
1	compound 21IBA 05/2015
1	Type 1 Angiotensin ReceptorIBA 05/2015
1	Type 2 Angiotensin ReceptorIBA 05/2015
1	Angiotensin IIIBA 05/2015
1	Cystatin CIBA 05/2015
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 06/2014
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2014
1	Ramipril (Altace)FDA LinkGeneric 01/2014
1	AlbuminsIBA 07/2011
1	CreatinineIBA 07/2011
1	Dietary Advanced Glycation End ProductsIBA 03/2010
1	ChloridesIBA 03/2010
1	Adenosine Triphosphate (ATP)IBA 03/2010
1	Antihypertensive Agents (Antihypertensives)IBA 01/2010
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2010
1	acetovanillone (apocynin)IBA 02/2008
1	EnzymesIBA 04/2007
1	Glutathione (Reduced Glutathione)IBA 04/2007
1	AntioxidantsIBA 04/2007
1	ApolipoproteinsIBA 04/2007
1	Perindopril FDA LinkGeneric 08/2005
1	Laminin (Merosin)IBA 11/2004
1	Protein Kinase CIBA 11/2004
1	SugarsIBA 01/2004

Therapy/Procedure

2	Therapeutics 01/2010 - 02/2007
1	Glycemic Control 07/2011